Press Releases

Intercytex announces introduction of Vavelta at FACE - the UK’s largest medical aesthetic conference

Cambridge, UK: Intercytex Group plc, the cell therapy company focused on aesthetic medicine and tissue repair, announces that it has introduced VAVELTA, its facial rejuvenation product, for the first time at the Facial Aesthetic Conference and Exhibition (FACE) held from 29th June to 1st July in London. FACE is the largest medical aesthetic conference in the UK for practitioners and clinics that deliver predominantly non-surgical medical aesthetic treatments.

VAVELTA is on track for launch in the second half of 2007 and will be launched initially with a selected group of physicians who have significant experience in the use of cell therapy for facial rejuvenation. It is expected that the first VAVELTA practitioners will be announced shortly.

Intercytex' stand at FACE focused on the use and underlying science of cell therapy in aesthetic medicine. It was supported by a presentation given to conference delegates by Dr Paul Kemp, Intercytex' Chief Scientific Officer, entitled 'From cells to cell therapy'.

VAVELTA incorporates the same cells, allogeneic human fibroblasts, as used in two other Intercytex products in development - ICX-SKN (skin graft replacement) and ICX-PRO (chronic wound healing).

Nick Higgins, Intercytex' CEO, said: "We are very pleased to have commenced the launch phase of VAVELTA. This represents the culmination of a considerable effort to complete the development of VAVELTA, a novel facial rejuvenation product which we will believe will make a considerable impact in the rapidly expanding aesthetic medicine market."

Enquiries

Notes for Editors
Intercytex is a cell therapy company which is focused on aesthetic medicine and tissue repair. It is using its proprietary expertise in cell therapy to develop products that harness the innate ability of human cells to regenerate and repair the body.

Intercytex has four products in development:

• ICX-PRO, designed to stimulate active repair in chronic wounds - in a Phase III trial
• Vavelta, a facial rejuvenation product to be launched in the second half of 2007
• ICX-SKN, being developed as a durable and robust skin replacement – recently completed a Phase I trial
• ICX-TRC, a hair regeneration product – in a Phase II trial

All Intercytex' products are derived from unmodified human cells.

Intercytex commenced operations in 2000 and currently employs around 75 staff. In addition to its head office in Cambridge, UK, it has a GMP clinical production facility with research and development laboratories in Manchester, UK. Additional laboratories are located in Boston, USA.

Intercytex' shares trade on AIM, a market of the London Stock Exchange, under the ticker symbol ICX.L.

Additional information on the Company can be found at www.intercytex.com

Statements contained within this press release may contain forward-looking information or statements with respect to the financial condition, results of operations and business achievements/performance of Intercytex and certain of the plans and objectives of management of Intercytex with respect thereto. By their nature, forward-looking statements involve risks and uncertainties that may cause actual results to vary from those contained in the forward-looking statements. In some cases, you can identify such forward-looking statements by terminology such as 'may', 'will', 'could', 'forecasts', 'expects', 'plans', 'anticipates', 'believes', 'estimates', 'predicts', 'potential', 'continue' or similar expressions. A number of factors, including the satisfactory progress of research and development, could cause Intercytex' actual financial condition, results of operations and business achievements/performance to differ materially from the estimates made or implied in such forward-looking statements and, accordingly, reliance should not be placed on such statements. Forward projections reflect management's best estimates based on information available at the time of issue and are not a guarantee of future performance. Other than as required by applicable law, Intercytex does not undertake any obligation to update or revise any forward-looking information or statements to reflect events or circumstances after the date of this release.

The term "Intercytex" refers to Intercytex Group plc and its subsidiary undertakings.